Policy | June 17, 2023
Health Ministry to prepare National Action Plan on AMR 2.0
Convergent action on AMR identified as an important area of intervention
Convergent action on AMR identified as an important area of intervention
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
UTD2 is the world's first oral epothilone microtubule inhibitor
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Subscribe To Our Newsletter & Stay Updated
